Antikörperneutralisierendes Humanes Respiratorisches Synzytialvirus
EP4748446
27. Mai 2026
Anmelder: Merck Sharp & Dohme LLC 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4748446
- Anmeldetag
- 27. Oktober 2016
- Veröffentlichung
- 27. Mai 2026
- Rechtsraum
- EP
- IPC
- C07K16/10, A61P31/14A61P31/14
Abstract
The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
Anmelder
- Firma
- Merck Sharp & Dohme LLC
- Land
- 🇺🇸 USA